High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D002712:Chlorides / Q000097:blood; D002986:Clinical Trials as Topic; D003005:Clopamide / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004039:Diet, Sodium-Restricted; D004231:Diuresis / Q000187:drug effects; D004357:Drug Synergism; D004487:Edema / Q000188:drug therapy*; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006929:Hyperaldosteronism / Q000150:complications*; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011188:Potassium / Q000097:blood / Q000652:urine; D012964:Sodium / Q000097:blood; D013148:Spironolactone / Q000008:administration & dosage*; D014223:Triamterene / Q000627:therapeutic use
D002712:Chlorides; D006852:Hydrochlorothiazide; D003005:Clopamide; D013148:Spironolactone; D005665:Furosemide; D012964:Sodium; D003404:Creatinine; D004976:Ethacrynic Acid; D011188:Potassium; D014223:Triamterene